Lypro Biosciences
US-based Lypro Biosciences innovatively tackles the insolubility issues of hydrophobic drugs.
Founded
2004US-based Lypro Biosciences innovatively tackles the insolubility issues of hydrophobic drugs.
Lypro Biosciences is a therapeutic development company based in Berkeley, United States. The company's core mission is to enhance the solubility and bioavailability of hydrophobic drugs and other therapeutic compounds through its proprietary drug delivery nanotechnology. Lypro's innovative platform, inspired by the body's natural mechanisms for transporting insoluble compounds, utilizes self-assembling, targetable nanometer-scale bioparticles called "NanoDisk" to facilitate targeted drug delivery.
Lypro Biosciences has made significant strides in addressing the challenges associated with hydrophobic drugs, potentially revolutionizing the way these compounds are delivered and utilized in medical treatments. The company's technology not only improves drug solubility but also ensures precise targeting to specific receptors, enhancing therapeutic efficacy and reducing side effects. This breakthrough has positioned Lypro as a key player in the field of drug delivery systems, contributing to advancements in pharmaceutical sciences and patient care.
Companies similar to Lypro Biosciences include Nanomedex Pharmaceuticals, Nanocopoeia, Leonardo Biosystems and Nano PharmaSolutions.
Lypro Biosciences was founded in 2004.
Lypro Biosciences' headquarters is located in Berkeley, CA, US.
Lypro Biosciences' most recent funding round was for $177.9k (USD) in September 2010.
As of Sep 6, 2010, Lypro Biosciences has disclosed funding of $177.9k (USD). Undisclosed round amounts are excluded.
Lypro Biosciences has 6 employees as of Feb 5, 2024.
Nano PharmaSolutions
